Biodegradable antibiotic implants and methods of their use in treating and preventing infections

Claim 1

A method of preventing or treating infection in a living patient at the site of a void in the patient's body created by surgery, comprising placing in a surgical void in a living patient a biodegradable implant, the implant comprising: at least one biodegradable material selected from the group consisting of polymers of lactic acid, oligomers of lactic acid, polymers of glycolic acid, oligomers of glycolic acid, copolymers of lactic and glycolic acid, and mixtures thereof; and a first antibiotic drug which is specific to treat or prevent infection from bacteria which are initially present at the site of the surgical void, and a second antibiotic drug which is specific to treat of prevent infection from bacteria which are not initially present as a bacterial population effective to cause infection at the site of the surgical void but will become present as a bacterial population effective to cause infection at the site of the surgical void at some time after the biodegradable implant is placed in the surgical void; whereby the implant provides a two-phase antibiotic elution rate, in which the first antibiotic drug is released from the implant at a higher rate than the second antibiotic drug when the implant is first placed in the surgical void, and at a subsequent time the second antibiotic drug is released from the implant at a higher rate than the first antibiotic drug.

Claim 2

A method of preventing or treating infection in a living patient at the site of a void in the patient's body created by surgery, comprising placing in a surgical void in a living patient a biodegradable implant, the implant comprising: at least one biodegradable material selected from the group consisting of polymers of lactic acid, oligomers of lactic acid, polymers of glycolic acid, oligomers of glycolic acid, copolymers of lactic and glycolic acid, and mixtures thereof; and a first antibiotic drug which is specific to treat or prevent infection from bacteria which are initially present at the site of the surgical void, and a second antibiotic drug which is specific to treat of prevent infection from bacteria which are not initially present as a bacterial population effective to cause infection at the site of the surgical void but will become present as a bacterial population effective to cause infection at the site of the surgical void at some time after the biodegradable implant is placed in the surgical void; whereby the implant provides a two-phase antibiotic elution rate, in which the first antibiotic drug is released from the implant at a higher rate than the second antibiotic drug when the implant is first placed in the surgical void, and at a subsequent time the second antibiotic drug is released from the implant at a higher rate than the first antibiotic drug.

Claim 4

A method of preventing or treating infection in a living patient at the site of a void in the patient's body created by surgery, comprising placing in a surgical void in a living patient a biodegradable implant, the implant comprising: biodegradable lactic acid polymers; and the antibiotic drugs clindamycin and vancomycin; where the weight ratio of lactic acid polymers to the antibiotic drugs is about 10:1 and the weight ratio of clindamycin to vancomycin is about 10:1, where the clindamycin is substantially totally released from the biodegradable implant into the surrounding tissue within a period of about 2-4 weeks after the biodegradable implant is placed into the surgical void, and where the vancomycin is substantially totally released from the biodegradable implant into the surrounding tissue within a period of about 6-10 weeks after the biodegradable implant is placed into the surgical void.

Claim 5

A method of preventing or treating infection in a living patient at the site of a void in the patient's body created by surgery, comprising placing in a surgical void in a living patient a biodegradable implant, the implant comprising: biodegradable lactic acid polymers; and the antibiotic drugs clindamycin and vancomycin; where the weight ratio of lactic acid polymers to the antibiotic drugs is about 10:1 and the weight ratio of clindamycin to vancomycin is about 10:1, where the clindamycin is substantially totally released from the biodegradable implant into the surrounding tissue within a period of about 2-4 weeks after the biodegradable implant is placed into the surgical void, and where the vancomycin is substantially totally released from the biodegradable implant into the surrounding tissue within a period of about 6-10 weeks after the biodegradable implant is placed into the surgical void.

Claim 14

A method of preventing or treating infection in a living patient at the site of a void in the patient's body created by surgery, comprising placing in a surgical void in a living patient a biodegradable implant, the implant comprising: at least one biodegradable material selected from the group consisting of polymers of lactic acid, oligomers of lactic acid, polymers of glycolic acid, oligomers of glycolic acid, copolymers of lactic and glycolic acid, and mixtures thereof; and a combination of antibiotic drugs selected from the group consisting of (a) clindamycin and vancomycin in a weight ratio of about 10:1, and (b) tobramycin and clindamycin in a weight ratio of about 10:1; where the weight ratio of the biodegradable material to the combination of antibiotic drugs is between about 50:1 and about 5:1.

Claim 15

A method of preventing or treating infection in a living patient at the site of a void in the patient's body created by surgery, comprising placing in a surgical void in a living patient a biodegradable implant, the implant comprising: at least one biodegradable material selected from the group consisting of polymers of lactic acid, oligomers of lactic acid, polymers of glycolic acid, oligomers of glycolic acid, copolymers of lactic and glycolic acid, and mixtures thereof; and a combination of antibiotic drugs selected from the group consisting of (a) clindamycin and vancomycin in a weight ratio of about 10:1, and (b) tobramycin and clindamycin in a weight ratio of about 10:1; where the weight ratio of the biodegradable material to the combination of antibiotic drugs is between about 50:1 and about 5:1.